ERAS dividend yield: 4.00%. JNJ dividend yield: 3.36%. ERAS is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in ERAS shares. Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.
ERAS is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in ERAS shares.
Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.
Is ERAS or JNJ better for dividend income in 2026?
ERAS currently offers a 4.00% yield (2.00/share/year) while JNJ offers 3.36% (4.96/share/year). ERAS provides higher current income. However, JNJ has grown its dividend faster (5.8% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in ERAS vs JNJ earn per year?
With $10,000 invested today: ERAS pays approximately $400/year. JNJ pays approximately $336/year. With DRIP reinvestment over 10 years, these grow to $899/year (ERAS) and $828/year (JNJ).
Does ERAS or JNJ pay monthly dividends?
ERAS pays quarterly dividends. JNJ pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this ERAS vs JNJ comparison by email
Save your analysis + get weekly dividend insights. Free forever.